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Abstract
Background: The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital
toxoplasmosis is not known.
Methods and Findings: Congenital toxoplasmosis was prospectively identified by universal prenatal or neonatal screening
in 14 European centres and children were followed for a median of 4 years. We evaluated determinants of postnatal death
or SNSD defined by one or more of functional neurological abnormalities, severe bilateral visual impairment, or pregnancy
termination for confirmed congenital toxoplasmosis. Two-thirds of the cohort received prenatal treatment (189/293; 65%).
23/293 (8%) fetuses developed SNSD of which nine were pregnancy terminations. Prenatal treatment reduced the risk of
SNSD. The odds ratio for prenatal treatment, adjusted for gestational age at maternal seroconversion, was 0.24 (95%
Bayesian credible intervals 0.07–0.71). This effect was robust to most sensitivity analyses. The number of infected fetuses
needed to be treated to prevent one case of SNSD was three (95% Bayesian credible intervals 2–15) after maternal
seroconversion at 10 weeks, and 18 (9–75) at 30 weeks of gestation. Pyrimethamine-sulphonamide treatment did not
reduce SNSD compared with spiramycin alone (adjusted odds ratio 0.78, 0.21–2.95). The proportion of live-born infants with
intracranial lesions detected postnatally who developed SNSD was 31.0% (17.0%–38.1%).
Conclusion: The finding that prenatal treatment reduced the risk of SNSD in infected fetuses should be interpreted with
caution because of the low number of SNSD cases and uncertainty about the timing of maternal seroconversion. As these
are observational data, policy decisions about screening require further evidence from a randomized trial of prenatal
screening and from cost-effectiveness analyses that take into account the incidence and prevalence of maternal infection.
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Introduction
Congenital toxoplasmosis occurs when a woman first acquires
Toxoplasma gondii infection during pregnancy. Infection can be
acquired from oocysts ingested from contaminated soil or water, or
tissue cysts from infected meat, but can only reliably be detected
by seroconversion (change from negative to positive toxoplasma-
specific antibodies) [1,2]. Overall, the proportion of mothers who
transmit infection to their fetus averages 25% but increases steeply
with the gestational age at maternal seroconversion [3,4].
Congenital toxoplasmosis leads to postnatal clinical manifestations
of retinochoroiditis and/or intracranial lesions in one in six (17%)
infected infants [3], and further eye lesions can appear at any age
[5]. Less is known about the risk of neurological impairment, even
though the main purpose of prenatal screening is to prevent
serious neurological sequelae or death (SNSD) [3]. No prospective,
comparative studies have evaluated the effectiveness of prenatal
treatment for reducing SNSD.
We used variation in screening practices across Europe to
determine the effect of prenatal treatment on SNSD. Our data
derive from two prospective cohort studies in 14 centres in six
European countries [6,7].
Methods
Study Population
We studied infected fetuses that were prospectively identified by
universal prenatal screening and newborn screening for congenital
toxoplasmosis [4,6–8]. Criteria for congenital toxoplasmosis are
reported elsewhere [4,6]. To avoid referral bias, we included only
mothers or children in whom a positive screen test result preceded
prenatal treatment or diagnostic investigations.
Follow-Up
Infected fetuses were enrolled into the study after confirmation
of a positive prenatal screening test in France, Austria, and Italy,
or neonatal screening test in Denmark, Sweden, or Poland.
Screening and treatment schedules are summarized in Tables 1
and 2. Information on clinical and laboratory findings and
treatment were collected at the end of pregnancy, at 1 mo
postnatally, and at every pediatric and ophthalmic examination for
toxoplasmosis at approximately 6 and 12 mo, and then annually
until at least 4 y of age [5,6].
Details recorded during pregnancy included the date of the first
abnormal or last normal fetal ultrasound scan, the results of PCR
testing of amniotic fluid for toxoplasma DNA, autopsy findings for
terminated fetuses, and the start and end dates of any prenatal
treatment. Mothers of infants detected in neonatal screening
centres were not treated. The variation between centres in the
delay before starting prenatal treatment after maternal serocon-
version and in the use of spiramycin or pyrimethamine-
sulphonamide combinations as first-line treatment is shown in
Table 1 for infected babies identified by universal prenatal
screening and in Table 2 for babies identified by neonatal
screening, and reported in detail elsewhere [6]. All centres treated
infected babies postnatally, but there were minor differences in the
use of pyrimethamine-sulphonamide alone or alternating with
spiramycin [6].
Serious Neurological Sequelae
The primary outcome was serious neurological sequelae or
death (SNSD), a composite outcome, comprising a pediatric report
at any age of microcephaly, insertion of intraventricular shunt, an
abnormal or suspicious neurodevelopmental examination that
resulted in referral to a specialist, seizures during infancy or at an
Table 1. Characteristics of universal prenatal screening protocols and patients in study centres.
Prenatal Screening France Austria Italy
All Prenatal
Screening
Years of recruitment 1996–1999 1996–2000 1996–2000
Centres Lyon, Paris, Marseille, Toulouse,
Nice, Reims, Grenoble
Vienna Milan, Naples
Screening and treatment schedules
Testing regimen PN monthly retesting PN + retesting
at 12, 20, 32 wk
PN monthly (Milan)
or 3-monthly
(Naples) retesting
First prenatal treatment Spiramycin P&S after 15 wk Spiramycin
n Fetuses with congenital toxoplasmosis 182 24 15 221
Percent treated prenatally 85 88 93 86
SNSD cases 2+9 terminations 1 2 14
GASC (wk)
Median imputed GASC (IQR) 29.0 (23.0–33.1) 18.8 (17.3–25.9) 18.5 (16.2–20.4) 27.3 (19.7–32.4)
Median interval (IQR) 4.0 (5.0–8.0) 17.1 (11.9–20.5) 12.6 (9.1–14.1) 5.4 (4.1–11.4)
Prenatal treatment
Total treated 135 21 14 189
Percent spiramycin as first treatment 88 10 93 79
Median imputed GASC to treatment
interval, wk (IQR)
2.9 (2.3–4.0) 11.0 (7.9–13.0) 5.9, (4.9–7.0) 3.1 (2.6–5.7)
Follow-up, y (IQR) 4.0 (3.2–4.8) 4.3 (4.0–5.1) 4.0 (1.0–4.1) 4.0 (3.2–4.7)
doi:10.1371/journal.pmed.1000351.t001
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older age that required anticonvulsant treatment, severe bilateral
visual impairment (visual acuity of Snellen 6/60 or less in both
eyes assessed after 3 y), cerebral palsy, or death from any cause
before 2 y of age including termination of pregnancy [9]. The
consistency of SNSD findings was checked through multiple
assessments. We did not require evidence that SNSD was
attributable to congenital toxoplasmosis as this difficult clinical
judgment could have biased inclusion of cases. Fetuses terminated
for congenital toxoplasmosis were assumed to have SNSD, owing
to long-standing policy discouraging termination unless there is
evidence of intracranial lesions or other adverse sequelae affecting
the fetus [10–12]. This assumption allows a conservative analysis
of the effect of prenatal treatment as women were always treated
before termination. Sensitivity analyses explored the increase in
treatment effect after assuming no SNSD for terminated fetuses.
Gestational Age at Maternal Seroconversion
In order to avoid well-known biases introduced by imputing a
covariate as an unadjusted midpoint for interval values of the
gestational age at maternal seroconversion (GASC), we imputed
values for GASC using all the serological information available to
us [13]. For women screened prenatally, we imputed seroconver-
sion at the midpoint between the last negative and first positive
immunoglobulin M (IgM) tests, unless the woman was IgG
negative at the first IgM positive test, when seroconversion was
assumed to be 14 d beforehand. This method was derived from a
previous analysis of a cohort from Lyon, France [14–16], and has
been confirmed with subsequent cohorts [6].
For babies identified by neonatal screening, maternal serocon-
version was based on an adjusted midpoint between conception, or
in Sweden and Denmark 1992–1996, between the first prenatal
booking sample and birth, using a previously reported log linear
regression model [5]. The model was derived in the cohort of
prenatal screened women and used ranked IgG titre and IgM
status at the first neonatal test as predictors of GASC. These
modifications shifted the imputed GASC to the right of the
midpoint. This shift is consistent with evidence that the probability
of a positive IgM result in an infected baby increases with GASC
and that increased IgG titre is associated with recent infection
[17,18].
Analyses
All live births had at least one pediatric assessment during
infancy (up till 12 mo old). Children with a normal pediatric
examination during infancy who were subsequently lost to follow-
up were assumed to have no SNSD [19].
We used WinBUGS version 1.4.3 to estimate odds ratios for the
effect of prenatal exposures on SNSD. All models were adjusted
for GASC [5]. The Bayesian framework was chosen because there
were numerical problems, caused by the low event rate and the
relatively small sample size, in the optimization algorithms
required to find maximum likelihood estimates, which meant that
the asymptotic normal approximation required to construct
confidence intervals was unreliable. The Bayesian framework
avoids relying on the large-sample normal approximation and has
the advantage of evaluating the uncertainty from derived,
nonlinear quantities without further using permutational or
resampling methods. An example of this type of propagation of
errors can be seen in the credible intervals presented in Figure 1.
Our inferences were based on 95% Bayesian credible intervals
(BCIs) referring to the posterior distributions of the models’
parameters and derived quantities. All models were adjusted for
gestational age at seroconversion, as previously reported [5].
The posterior probability distributions of SNSD for each level of
exposure were calculated using Markov Chain Monte Carlo
(MCMC) iterations. We used noninformative priors in two mixing
Markov chains with different starting values and allowed 1,000
MCMC burn-in iterations; estimates of all posterior distributions
were based on 10,000 realizations of each chain. A linear
transformation was applied to the imputed values of gestational
age at maternal seroconversion by centering around its mean; this
improved the MCMC convergence, assessed by the method
proposed by Brooks and Gelman [20], and made the autocorre-
lation functions close to zero. Inclusion of a quadratic term for
GASC did not improve the goodness of fit according to the
Deviance Information Criterion [21]. This method produced
Table 2. Characteristics of neonatal screening protocols and patients in study centres.
Neonatal Screening Sweden Poland Denmark
Denmark
1992–1996
All Neonatal
Screening
Years of recruitment 1997–1998 1996–2000 1997–2000 1992–1996
Centres Stockholm, South
Sweden
Poznan Copenhagen National study
Screening and treatment schedules
Testing regimen Neo, IgGR and IgM Neo, IgM and IgA Neo, IgM and IgA Neo, IgGR and IgM
First prenatal treatment
n Fetuses with congenital toxoplasmosis 3 29 14 26 72
Percent treated prenatally 0 0 0 0 0
SNSD cases 1 4 1 3 9
GASC (wk)
Median imputed GASC (IQR) 27.9 (27.3–27.9) 27.6 (26.9–29.4) 26.9 (26.9–27.5) 27.5 (26.8–29.6) 27.3 (26.9–29.2)
Median interval (IQR) 28.1 (26.1–30.6) 38.4 (36.4–40.6) 40.0 (40.0–40.0) 31.1 (29.2–32.4) 36.4 (31.5–40.0)
Follow-up, y (IQR) 3.9 (3.8–4.6) 4.1 (3.9–4.3) 3.5 (3.2–3.9) 6.3 (4.9–6.4) 4.2 (3.5–6.1)
IgGR involves detection of IgG seroconversion by comparing neonatal sample with prenatal booking sample from mother.
Neo, neonatal screening based on detection of specific antibodies in Guthrie card bloodspots; P&S, pyrimethamine and sulphonamide; PN, prenatal screening.
doi:10.1371/journal.pmed.1000351.t002
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similar results for the effect of prenatal treatment to a previously
used maximum likelihood estimation procedure [6].
Sensitivity analyses were used to determine the robustness of the
findings to different assumptions. First we explored under-
reporting of terminations by excluding data from Austria and
Italy, as no terminations were reported for these centres. We also
determined whether adding 18 unreported terminated fetuses to
the analyses would alter the treatment effect. The 18 unreported
fetuses had the same characteristics (GASC and prenatal
treatment delay) as the nine terminated fetuses included in the
study. Second, we estimated the effect of treatment under the
extreme assumption that all terminated fetuses would have been
born alive and would have developed normally. We revised this
analysis assuming that the three fetuses with normal fetal
ultrasound scans and no evidence of disseminated infection would
have developed normally, even though two fetuses had their last
scan before 21 wk of gestation. Third, we reclassified three live-
born, untreated children with SNSD but without intracranial
calcification as no SNSD. This reclassification restricted the
outcome of SNSD to cases almost certainly attributable to
congenital toxoplasmosis. Fourth, we explored potential error in
the imputed gestational age at maternal seroconversion for
children identified by neonatal screening by assuming serocon-
version 1 mo earlier.
We calculated the number of women needed to be treated
(NNT) to prevent one case of SNSD as a clinically meaningful
measure for counseling women about the absolute difference in the
probability of their child developing SNSD with and without
treatment. We used the posterior probability distributions and
95% credible interval calculated from the regression model to
estimate the NNT for women after a positive prenatal diagnosis
(i.e., the number of women with an infected fetus who need to be
treated). To estimate the NNT for women without prenatal
diagnosis, we multiplied the difference in probability with the
Figure 1. Probability of SNSD. Probability of SNSD according to imputed gestational age at seroconversion and 95% Bayesian credible limits:
dotted lines denote treated pregnancies; solid lines denote untreated pregnancies.
doi:10.1371/journal.pmed.1000351.g001
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estimated risk of mother to child transmission of toxoplasmosis
derived from a meta-analysis of all available cohort studies [3].
This simple estimation was based on the assumption that prenatal
treatment has no effect on mother to child transmission. We did
not take into account random error in the estimation of mother to
child transmission according to GASC.
To inform prognostic counseling for parents of live-born babies,
we determined the probability of SNSD according to an exclusive
hierarchy of postnatal clinical manifestations (ventricular dilatation
and/or intracranial calcification, lymphadenopathy or hepato-
splenomegaly, and/or retinochoroiditis) that would be apparent
after pediatric examination, ophthalmoscopy, and postnatal
cranial ultrasound completed by 6 mo postnatal age [1]. These
analyses excluded the Danish cohort of 1992 to 1996 (n=26)
owing to missing data for these early manifestations [7].
Research ethics approval was granted in countries where
screening was offered as part of a research study [7,22,23], but
was not required where screening was routine practice.
Results
Study Population and Neurological Sequelae
The combined cohorts comprised 293 infected fetuses, of whom
284 were born alive. 23 fetuses consisting of nine terminated
pregnancies and 14 live-born children died or were classified as
having serious neurological sequelae (Tables 1–4).The distribution
of GASC and the intervals from which GASC was imputed are
summarized in Tables 1 and 2, and Figures S1 and S2. All live-
born children had at least one pediatric examination. The last
examination was before 6 mo of age for 6/284 (2%) children and
between 9 and 12 mo for a further six children. 238/284 (84%)
children were followed beyond 2 y of age. Overall, the median
duration of follow-up was 4.05 y (interquartile range [IQR] 3.21–
4.88). Follow-up was longer for 26 children enrolled in the Danish
cohort in 1992–1996 (6.3 y, IQR 4.9–6.4) (Table 2), but did not
differ significantly between live-born children whose mothers were
treated (4.05, IQR 3.25–4.76) compared with not treated (4.13,
IQR 3.17–5.19, Wilcoxon-Mann-Whitney test p=0.39).
Of the 221 women identified by prenatal screening, 86% (189/
221) received prenatal treatment, most (71%, 134/189) within
5 wk of the imputed date of maternal seroconversion (Table 4).
Untreated women (n=32) identified by prenatal screening had
their first positive serological test at a median gestational age of
38.6 wk (IQR 37.4–40.0 wk). None of the 72 women with infected
live-born infants identified by neonatal screening received prenatal
treatment (Table 2).
The characteristics of the 23 fetuses with SNSD are summarized
in Tables 3 and 4. Among the 14 live births, most (11/14) had
SNSD first detected in the first 6 mo of life. Three untreated, live-
born children had no intracranial lesions detected postnatally.
Two of the three were identified by neonatal screening. One had
no ocular manifestation but was classified with SNSD because the
baby died at 3 mo from staphylococcal septicemia. The other two
had ocular signs: one had retinochoroiditis and strabismus and the
other had a cataract. Less information was available for the nine
terminated fetuses (Table 4): six had intracranial abnormalities on
fetal ultrasound and/or macroscopic abnormalities at autopsy.
Characteristics Associated with Serious Neurological
Sequelae
Three prenatal factors strongly predicted serious neurological
sequelae: the gestational age at maternal seroconversion, prenatal
treatment, and an abnormal fetal ultrasound of the brain (Table 4).
The odds of SNSD, adjusted for prenatal treatment, decreased by
13% (95% BCI 7%–19%) for every week increase in gestational
age at maternal seroconversion (odds ratio 0.866, 95% BCI 0.806–
0.925) (Table 5).
Prenatal treatment substantially reduced the risk of serious
neurological sequelae. The adjusted odds ratio for any prenatal
treatment compared with no treatment was 0.236 (95% BCI
0.071–0.708), and the average risk difference between treated and
untreated mothers was 8.7% (2.0%–18.1%) (Table 5). In infected
fetuses, the absolute risk difference between SNSD in treated and
untreated pregnancies declined steeply with the gestational age at
maternal seroconversion (Figure 1). After maternal seroconversion
Table 3. Characteristics of live births with congenital toxoplasmosis and SNSD.
Characteristic Neonatal screened (n=9) Prenatal screened (n=5)
Prenatal and birth
Treated prenatally 0 4
Abnormal fetal ultrasound 2 (4 NR) 3
Gestational age at birth 26–42 wk 34–39
Clinical manifestations before #6 mo
Intracranial lesions (postnatal cranial ultrasound) 7 4
Retinochoroidits 5 (1 NR) 4
Lymphadenopathy/hepatosplenomegaly 2 (3 NR) 3
Outcomes reported during follow-up
Death before 2 y 3 1
Microcephaly, seizures, or shunt required 5 4
Cerebral palsy or abnormal neurological developmenta 5 3
Ocular complicationsb 5 5
Blindness (#6/60) 1 (4 NR) 2 (1 NR)
aAbnormal or suspicious neurological examination leading to referral to a specialist.
bOcular microphthalmia (n among all live births with SNSD= 5), visual opacities (n=4), cataract (n= 2), strabismus (n=4).
NR, not reported.
doi:10.1371/journal.pmed.1000351.t003
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at 10 wk of gestation, the estimated risk of SNSD in fetuses of
treated women was 25.7% (12.9%–43.0%) and in untreated
women 60.0% (27.6%–85.9%). The risk difference was 33.3%
(6.9%–56.1%), and the NNT of mothers with infected fetuses to
prevent one case of SNSD was 3 (2–15). After seroconversion at
20 wk, the risk difference was 18.5 (3.6–38.3, NNT 6 [3–28]), and
after seroconversion at 30 wk, the risk difference was 5.7 (1.3–
11.5, NNT 18 [9–75]). The NNT to prevent one case of SNSD for
women who do not know whether their fetus is infected or not was
estimated to be 28 (17–132) after seroconversion at 10 wk of
gestation; 20 (10–99) at 20 wk, the lowest point; 32 (16–137) at
30 wk; and 51 (23–201) after seroconversion at 35 wk of gestation.
These estimates apply only to women with confirmed serocon-
version.
Table 6 shows that sensitivity analyses did not alter the finding
of a significant treatment effect at the 5% level, except when three
untreated live-born children with SNSD but no intracranial lesions
were reclassified without SNSD. The adjusted odds ratio for any
prenatal treatment compared with none was reduced in analyses
that excluded Austria and Italy and when terminated fetuses were
reclassified without SNSD (Table 6). The addition of a further 18
fictitious, unreported pregnancy terminations with SNSD mar-
ginally reduced the treatment effect. Assuming maternal serocon-
version 1 mo earlier in cases identified by neonatal screening also
increased the odds ratio, but the upper 95% credible interval still
excluded 1.0 (Table 6).
The nine terminated pregnancies in France made up most of
the SNSD cases that seroconverted in the first trimester (Figures
S1 and S2). As a result, the effect of GASC on SNSD diminished
and was no longer significant at the 5% level when all terminations
were reclassified without SNSD (Table 6).
Among treated women, we found no evidence that delayed
timing of treatment increased the proportion of fetuses with
SNSD. However, the power to detect such an effect was limited.
Moreover, most of the early treated fetuses with SNSD were
pregnancy terminations (Table 4). There was no evidence that
pyrimethamine-sulphonamide treatment was clinically or statisti-
cally more beneficial than spiramycin alone, although there was
limited power to detect an effect at the 5% level (Table 5).
Fetal ultrasound abnormality was associated with SNSD
(adjusted odds ratio 120, 7.04–6400), partly because this was a
criterion for pregnancy termination, and hence classification with
SNSD. The earliest gestational age at detection of intracranial
abnormality on fetal ultrasound was 21 wk in five terminated
fetuses and 26 wk in five live-born fetuses (three with SNSD). All
five live-born fetuses with intracranial abnormality on fetal
ultrasound had intracranial calcification and/or ventricular
dilatation on postnatal cranial ultrasound (specificity 178/178,
100%), but few babies with abnormal postnatal scans had
intracranial abnormalities reported on fetal ultrasound (5/18,
sensitivity 28%).
Table 7 shows the distribution of serious neurological sequelae
according to postnatal clinical manifestations detected in early
infancy in live-born children with congenital toxoplasmosis. The
proportion of children with serious neurological sequelae was
higher among those with intracranial lesions detected by postnatal
cranial ultrasound scan (30.2%, 95% BCI 13.7%–46.6%) than in
those with no intracranial lesions (1.0%, 0.0%–2.3%).
Discussion
Prenatal treatment substantially reduced the proportion of
infected fetuses who developed SNSD. We found no evidence that
a pyrimethamine-sulphonamide combination was more effective
than spiramycin, which is less toxic [24]. Among infected fetuses,
the difference in the proportion of treated and untreated fetuses
with SNSD was highest when maternal infection was acquired
during the first trimester. These findings should be interpreted
with caution because of the low number of the SNSD cases and
the uncertainty about the timing of maternal seroconversion.
Abnormalities on fetal ultrasound, and intracranial abnormalities
detected by cranial ultrasound after birth, were important
prognostic markers for SNSD.
This is the first prospective cohort study, to our knowledge, to
report the effect of prenatal treatment on serious neurological
sequelae in fetuses with congenital toxoplasmosis. We minimized
selective inclusion of pregnancies with complications ensuring that
universal screening tests preceded prenatal treatment or diagnostic
investigations for fetal infection status or abnormalities. Long-term
follow-up and repeated pediatric assessments made it possible to
ensure that, for the live births at least, SNSD were confirmed. In a
retrospective study, Foulon et al. reported a similarly large effect of
prenatal treatment on intracranial lesions and/or neurological
sequelae detected up to 12 mo of age, but these results could have
been explained by referral of untreated women with pregnancy
complications to fetal medicine centres [25,26].
Weaknesses of the study relate to selection biases inherent in
observational studies. First, pregnancies terminated for fetal
infection may not have been reported to the study [27], but
sensitivity analyses that assumed twice as many treated women
Table 4. Characteristics of fetuses terminated with congenital toxoplasmosis.
Characteristic
Abnormal Fetal Ultrasounda
(n=5) Normal Fetal Ultrasound (n=4)
Gestational age at maternal seroconversion (wk) 10–17 8–13
Gestational age at first abnormal or last normal fetal ultrasound (wk) 21–30 11–23
Termination of pregnancy (wk of gestation) 22–33 12–24
Autopsy findings (n fetuses affected)
Macroscopic examination not reported 1 3
Intracranial abnormalities 1 —
Myocarditis, pneumonitis, disseminated disease 1 1
Nil abnormal found 2 —
All fetuses had positive PCR detection of T. gondii DNA in amniotic fluid (n= 8) or culture based on mouse inoculation of fetal products (n= 3).
aIntracranial calcification or ventricular dilatation on fetal ultrasound scan.
doi:10.1371/journal.pmed.1000351.t004
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had ‘‘unreported’’ terminations did not nullify the treatment effect.
Second, we did not include stillbirths in the analysis as these rarely
have a definitive diagnosis of congenital toxoplasmosis [28], which
could have underestimated the benefits of prenatal treatment if
treatment led to the survival of fetuses with SNSD who would have
miscarried or been stillborn in untreated women. Third, our
method for estimating the gestational age at maternal serocon-
version may have overestimated precision and could have
introduced bias [13]. Fourth, we assumed that all SNSD outcomes
were attributable to congenital toxoplasmosis. Reclassification of
three children with SNSD but without intracranial lesions to non-
SNSD rendered the effect of prenatal treatment nonsignificant at
the 5% level. Fifth, adverse outcomes were limited to serious
manifestations that were evident on pediatric examination in the
early childhood years. Overall, these potential biases act in
different directions and are likely to only partly account for the
strong treatment effect observed. However, they may alter the
magnitude of the effect, which can only be reliably determined by
a large randomized controlled trial.
Implications for Practice
The benefits of prenatal treatment are high for women with a
positive prenatal diagnosis for congenital toxoplasmosis. The NNT
to prevent one case of SNSD varies from three to 18 depending on
the gestational age at maternal seroconversion. As fetal diagnosis
carries a risk of fetal loss due to amniocentesis, some women may
Table 5. Prenatal characteristics associated with SNSD.
Characteristic
Total Infected
Fetuses (n)
Fetuses with
SNSD (n)
Odds Ratio
for SNSDa 95% BCI
Estimated
proportion (%)
with SNSDa 95% BCI
Terminated Live Birth
All children 293 9 14 7.73 (5.11–11.21)
Imputed GASC
Per week of gestation 0.904 0.855–0.953
#20 wk 57 9 4 Ref. — 22.81 13.00–34.29
.20 wk 236 0 10 0.290 0.148–0.520 4.12 2.03–7.12
Screening centre
Neonatal 72 0 9 Ref. — 14.95 7.42–25.69
Prenatal 221 9 5 0.170 0.046–0.534 2.90 1.04–6.12
Country
France 182 9 2 Ref. — 3.18 1.14–6.75
Italy/Austria 39 0 3 0.444 0.083–1.784 1.42 0.23–5.56
Scandinavia 43 0 5 4.798 1.202–19.24 13.58 5.05–27.29
Poland 29 0 4 5.981 1.28–26.94 16.40 5.21–34.62
Gestation at birthb
Term 246 0 10 Ref. — 3.82 1.91–6.79
Preterm 38 9 4 2.679 0.653–9.195 9.62 2.87–22.08
Genderb 5 unknown
Girl 130 2 5 Ref. — 3.46 1.24–7.66
Boy 154 2 9 1.625 0.524–5.381 5.51 2.64–9.89
Fetal ultrasoundc
Normal 204 4 2 Ref. — 0.59 0.71–2.28
Any abnormality 14 5 3 120 7.035–6400 42.63 6.09–90.16
Prenatal treatment
Untreated 104 0 10 Ref. — 11.99 6.02–20.82
Treated 189 9 4 0.236 0.071–0.708 3.11 1.21–6.47
Type of treatmentd
Spiramycin only 87 5 2 Ref. — 2.37– 0.48–7.62
Any P&S treatment 102 4 2 0.777 0.204–2.849 1.84 0.43–5.39
Treatment delay after seroconversiond
#35 d 134 6 1 Ref. — 0.45 0.02–2.54
.35 d 55 3 3 0.7581 0.190–2.862 2.83 0.34–11.00
aAdjusted for gestational age at maternal seroconversion.
bSample restricted to live births.
cSample restricted to mother-child pairs in prenatal centres who had fetal ultrasound (218/221).
dSample restricted to those prescribed prenatal treatment.
P&S, pyrimethamine and sulphonamide treatment.
doi:10.1371/journal.pmed.1000351.t005
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Table 6. Sensitivity analyses (odds ratios for SNSD and 95% BCIs).
Rationale for Sensitivity Analysis
Infected
Fetuses (n) SNSD (n) Univariable Model Multivariable Model
GASC Adjusted GASC
Prenatal Treatment
Versus None
OR 95% BCI OR 95% BCI OR 95% BCI
Analytic approach
Bayesian estimate 293 23 0.904 (0.855–0.953) 0.866 (0.806–0.925)0.236 (0.071–0.708)
Ordinary logistic regression 293 23 0.903 (0.857–0.953) 0.870 (0.814–0.930)0.248 (0.081–0.756)
Varying outcome status
Under-reporting of terminations
Excluding Italy and Austria 254 11 0.882 (0.829–0.936) 0.819 (0.741–0.889)0.123 (0.025–0.461)
Addition of 18 fictitious unreported
terminations
311 41 0.849 (0.806–0.889) 0.817 (0.763–0.867)0.294 (0.096–0.850)
Assumption of adverse outcome
in terminated fetuses
No terminations have SNSD 293 14 0.999 0.931–1.082) 0.948 (0.870–1.035)0.136 (0.029–0.498)
Terminations with normal fetal
ultrasound and no disseminated
disease have no SNSD
293 20 0.926 (0.875–0.980) 0.890 (0.829–0.951)0.226 (0.067–0.692)
Outcomes not attributable to
congenital toxoplasmosis
Three live births without intracranial
lesions reclassified as not SNSD
293 20 0.889 (0.838–0.941) 0.865 (0.804–0.923)0.367 (0.104–1.230)
One live birth without intracranial
lesions and no ocular signs reclassified
as not SNSD
293 22 0.902 (0.853–0.952) 0.871 (0.811–0.927)0.287 (0.085–0.858)
Timing of GASC
Imputed GASC placed 1 mo
earlier in neonatal screened.
293 23 0.883 0.830–0.935) 0.861 (0.798–0.919)0.356 (0.125–0.992)
OR, odds ratio.
doi:10.1371/journal.pmed.1000351.t006
Table 7. Postnatal clinical manifestations detected in early infancy and probability (%) of SNSD.
Postnatal Clinical Manifestations Postnatal Clinical Manifestations Detected at #6 mo Old
SNSD Total Infected
n=11 n=258a
All three signs (brain/eye/LHS) 4 4
Brain + eye 3 7
Brain + LHS 1 4
Brain only 1 15
Total with brain lesions 9 30
Proportion with SNSD (95% BCI) 30.2% (13.7%–46.6%)
Eye + LHS 0 1
Eye only 0 13
LHS only 0 6
None 2 208
Total without brain lesions 2 228
Proportion with SNSD (95% BCI) 1.0% (0.0%–2.3%)
Brain, intracranial calcification or ventricular dilatation detected on postnatal cranial ultrasound examination; eye, retinochoroiditis; LHS, lymphadenopathy or
hepatosplenomegaly.
aSample excludes Danish cohort recruited 1992–1996.
doi:10.1371/journal.pmed.1000351.t007
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prefer to trade a lower chance of benefit in order to avoid
amniocentesis, provided a treatment such as spiramycin is used,
which has no serious side effects [24]. The lowest estimate of the
number of women with no prenatal diagnosis and unknown
congenital infection status of their fetus who need to be treated to
prevent one case of SNSD was 20 (ten to 99) after maternal
seroconversion at 20 wk of pregnancy, rising to 28 (17 to 132) after
seroconversion at 10 wk and 51 (23, 201) at 35 wk of gestation.
These estimates apply only to women with confirmed serocon-
version. The NNT would be much higher for women whose
infection is diagnosed by tests for recent infection such as a rising
titre, or low IgG avidity, as most of these women would have
acquired infection before conception [4,29].
Termination of pregnancy should be limited to fetuses with
abnormal intracranial ultrasound findings, otherwise the vast
majority of terminations would involve unaffected fetuses; this
means deferring termination until 22 wk or later as ultrasound
abnormalities do not develop until 21 wk of gestation at the
earliest [30]. Termination at this late gestation involves feticide
and is unlikely to be acceptable to many women or clinicians.
In terms of the type of treatment, our findings add to previous
comparative studies, which have consistently found no evidence
that pyrimethamine-sulphonamide combinations are more effec-
tive than the less toxic alternative of spiramycin [3,4,6,15,16,25].
However, our study lacked power to detect an effect on SNSD.
Whether the benefits of prenatal treatment translate into an
effective prenatal screening program remains to be determined by
a randomised controlled trial of prenatal screening. In the
meantime, cost-effectiveness analyses that take into account
regional variation in the prevalence of susceptible women, the
incidence of maternal infection, the timing, uptake, and accuracy
of repeated screening tests to detect maternal seroconversion, and
the timing of prenatal treatment, could provide valuable
information for policy makers and for research funders contem-
plating investment in a large trial.
Finally, our results relate to the relatively benign type II strain of
T. gondii, which predominates in Europe and North America.
Trials are urgently needed to determine the most effective timing
and type of prenatal treatment for the more virulent parasite
strains that predominate in South America [31].
Supporting Information
Figure S1 Interval for gestational age at seroconversion for
pregnancies affected by SNSD. The vertical lines show the GASC
interval for each pregnancy affected by SNSD (n=23). Colours
denote country of birth: red, France; yellow, Italy; light green,
Austria; dark green, Poland; light blue, Denmark 1997–2000;
purple, Denmark 1992–1996; pink, Sweden.
Found at: doi:10.1371/journal.pmed.1000351.s001 (0.01 MB
PDF)
Figure S2 Interval for gestational age at seroconversion for
unaffected pregnancies. The vertical lines show the GASC interval
for each unaffected pregnancy (n=270). Colour codes as for
Figure S1.
Found at: doi:10.1371/journal.pmed.1000351.s002 (0.01 MB
PDF)
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Editors’ Summary
Background. Toxoplasmosis is a very common parasitic
infection. People usually become infected with Toxoplasma
gondii, the parasite that causes toxoplasmosis, by eating raw
or undercooked meat that contains the parasite, but it can
also be contracted by drinking unfiltered water or by
handling cat litter. Most people with toxoplasmosis never
know they have the disease. However, if a pregnant woman
becomes infected with T. gondii, she can transmit the
parasite to her unborn baby (fetus). Overall, about a quarter
of women who catch toxoplasmosis during pregnancy
transmit the parasite to their fetus. If transmission occurs
early during pregnancy, the resultant ‘‘congenital
toxoplasmosis’’ increases the risk of miscarriage and the
risk of the baby being born with brain damage, epilepsy,
deafness, blindness, or developmental problems (‘‘serious
neurological sequelae’’). In the worst cases, babies may be
born dead or die soon after birth. Congenital toxoplasmosis
caught during the final third of pregnancy may not initially
cause any health problems but eyesight problems often
develop later in life.
Why Was This Study Done? Clinicians can find out if a
woman has been infected with T. gondii during pregnancy
by looking for parasite-specific antibodies (proteins made by
the immune system that fight infections) in her blood. If the
pattern of antibodies suggests a recent infection, the woman
can be given spiramycin or pyrimethamine-sulfonamide,
antibiotics that are thought to reduce the risk of
transmission to the fetus and the severity of toxoplasmosis
in infected fetuses. In some countries where toxoplasmosis is
particularly common (for example, France), pregnant women
are routinely screened for toxoplasmosis and treated with
antibiotics if there are signs of recent infection. But is
prenatal treatment an effective way to prevent the serious
neurological sequelae or postnatal death (SNSD) associated
with congenital toxoplasmosis? In this observational study,
the researchers examine this question by studying a group of
children identified as having congenital toxoplasmosis by
prenatal or neonatal screening in six European countries. An
observational study measures outcomes in a group of
patients without trying to influence those outcomes by
providing a specific treatment.
What Did the Researchers Do and Find? The researchers
followed 293 children in whom congenital toxoplasmosis
had been identified by prenatal screening (in France, Austria,
and Italy) or by neonatal screening (in Denmark, Sweden,
and Poland) for an average 4 years. Two-thirds of the
children received prenatal treatment for toxoplasmosis and
23 fetuses (8% of the fetuses) developed SNSD; nine of these
cases of SNSD were terminated during pregnancy. By
comparing the number of cases of SNSD among children
who received prenatal treatment with the number among
children who did not receive prenatal treatment, the
researchers estimate that prenatal treatment reduced the
risk of SNSD by three-quarters. They also estimate that to
prevent one case of SNSD after maternal infection at 10
weeks of pregnancy, it would be necessary to treat three
fetuses with confirmed infection. To prevent one case of
SNSD after maternal infection at 30 weeks of pregnancy, 18
fetuses would need to be treated. Finally, the researchers
report that the effectiveness of pyrimethamine-sulfonamide
and spiramycin (which is less toxic) was similar, and that a
third of live-born infants with brain damage that was
detected after birth subsequently developed SNSD.
What Do These Findings Mean? These findings suggest
that prenatal treatment of congenital toxoplasmosis could
substantially reduce the proportion of infected fetuses that
develop SNDS and would be particularly effective in fetuses
whose mothers acquired T. gondii during the first third of
pregnancy. These findings should be interpreted with
caution, however, because of the small number of affected
fetuses in the study and because of uncertainty about the
timing of maternal infection. Furthermore, these findings
only relate to the relatively benign strain of T. gondii that
predominates in Europe and North America; further studies
are needed to test whether prenatal treatment is effective
against the more virulent strains of the parasite that occur in
South America. Finally, because this study is an observational
study, its findings might reflect differences between the
study participants other than whether or not they received
prenatal treatment. These findings need to be confirmed in
randomized controlled trials of prenatal screening, therefore,
before any policy decisions are made about routine prenatal
screening and treatment for congenital toxoplasmosis.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000351.
N The US Centers for Disease Control and Prevention
provides detailed information about all aspects of toxo-
plasmosis, including toxoplasmosis in pregnant women (in
English and Spanish)
N The UK National Health Services Choices website has
information for patients about toxoplasmosis and about
the risks of toxoplasmosis during pregnancy
N KidsHealth, a resource maintained by the Nemours
Foundation (a not-for-profit organization for children’s
health), provides information for parents about toxoplas-
mosis (in English and Spanish)
N Tommy’s, a nonprofit organization that funds research on
the health of babies, also has information on toxoplasmo-
sis
N MedlinePlus provides links to other information on
toxoplasmosis (in English and Spanish)
N EUROTOXO contains reports generated by a European
consensus development project
N Uptodate provides information about toxoplasmosis and
pregnancy
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